Impact of Ibis on Patients With Advanced COPD

Overview

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients with COPD.

Full Title of Study: “Impact of Ibis, a Digital Health Solution for Patient Activation and Early Intervention, on Acute Care Utilization by Patients With Advanced COPD”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Supportive Care
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 2018

Interventions

  • Behavioral: Digital Therapeutics

Arms, Groups and Cohorts

  • Experimental: Digital Therapeutics
    • Patients assigned to the digital therapeutics arm will receive Ibis and all the associate services.
  • No Intervention: Control

Clinical Trial Outcome Measures

Primary Measures

  • Reduction in Acute Care Utilization
    • Time Frame: 6 months and then again at 1 year

Participating in This Clinical Trial

Inclusion Criteria

  • Gold Stage II with a CAT Score above 19
  • Gold Stage III/IV with a CAT Score above 14

Exclusion Criteria

  • Cognitive or physical impediments that inhibits patients from interacting with our digital therapeutics platform.

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Senscio Systems
  • Collaborator
    • Central Maine Medical Family
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.